Headlines about Maximus (NYSE:MMS) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Maximus earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the health services provider an impact score of 46.8203250159593 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of NYSE MMS traded down $1.21 during mid-day trading on Friday, hitting $65.59. The company’s stock had a trading volume of 330,126 shares, compared to its average volume of 344,731. The firm has a market capitalization of $4,277.98, a PE ratio of 21.65, a price-to-earnings-growth ratio of 2.26 and a beta of 1.12. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.01. Maximus has a one year low of $57.12 and a one year high of $72.71.
Maximus (NYSE:MMS) last announced its quarterly earnings results on Thursday, February 8th. The health services provider reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.01. The business had revenue of $623.10 million for the quarter, compared to the consensus estimate of $624.36 million. Maximus had a net margin of 8.99% and a return on equity of 22.93%. Maximus’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the company posted $0.71 EPS. equities research analysts anticipate that Maximus will post 3.31 earnings per share for the current fiscal year.
A number of brokerages have commented on MMS. Zacks Investment Research raised shares of Maximus from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a report on Tuesday, February 13th. Canaccord Genuity decreased their price objective on shares of Maximus from $71.00 to $65.00 and set a “hold” rating on the stock in a report on Friday, February 9th. Finally, Maxim Group reissued a “hold” rating and set a $69.00 price objective (up previously from $66.00) on shares of Maximus in a report on Thursday, February 8th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. Maximus has a consensus rating of “Hold” and a consensus target price of $66.60.
In other news, Director Russell A. Beliveau sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $66.55, for a total transaction of $66,550.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel David Francis sold 3,600 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $64.50, for a total transaction of $232,200.00. Following the transaction, the general counsel now directly owns 10,017 shares of the company’s stock, valued at $646,096.50. The disclosure for this sale can be found here. Insiders have sold a total of 44,600 shares of company stock worth $3,009,650 over the last 90 days. Corporate insiders own 3.10% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Maximus (MMS) Receiving Somewhat Favorable News Coverage, Report Shows” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/08/maximus-mms-receives-media-sentiment-score-of-0-14.html.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services programs in the United States, the United Kingdom, Australia, Canada, Singapore, and Saudi Arabia. The company's Health Services segment offers various BPS, appeals, and assessments, as well as related consulting services for state, provincial, and national government programs comprising Medicaid, Children's Health Insurance Program, the Affordable Care Act, Health Insurance British Columbia, the Health Assessment Advisory Service, and Preadmission Screening and Resident Reviews.
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.